Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Nerdwallet Inc (NRDS) Price & Performance

AstraZeneca plcTrade
Nerdwallet IncTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Nerdwallet Inc — how do they compare? AstraZeneca plc trades at $158.63 (market cap $248.14B), while Nerdwallet Inc trades at $9.46 (market cap $625.17M). The key difference: AstraZeneca plc is far larger — about 396.9× Nerdwallet Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.

AZNNRDS
Market Cap
$248.14B$625.17M
Sector
HealthFinancials
52-Week High
$209.48$15.93
52-Week Low
$147.06$7.58
Enterprise Value
$275.41B$539.47M
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.

The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.

Nerdwallet Inc

NerdWallet (NRDS) trades at $9.48, down 3.27% today, amid mixed signals. The stock shows bullish technical momentum with a 10.87 P/E ratio indicating potential undervaluation. Revenue grew to $836.6M in 2025, with net income reaching $48.7M, though Q2 2026 earnings missed expectations. Positive analyst sentiment includes a 66.66% buy rating, with news highlighting a 27.9% upside potential from Zacks Investment Research on August 10, 2026.

Outlook is cautiously optimistic with strong profitability margins and cash flow growth, but risks include organic-search pressure and competitive threats. The stock's valuation and recent momentum suggest upside, though investors must monitor earnings consistency and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS